Servify Enables Samsung Care+ for Business in Canada
14.6.2022 15:30:00 EEST | Business Wire | Press release
Servify, a global AI-driven product ownership experience platform, announced its partnership with Samsung Electronics Canada to roll out its premium protection plan for corporate devices: Samsung Care+ for Business. The service is designed exclusively for nationwide enterprises and government customers.
After a successful launch last year in the US market where the Samsung B2B program has been well received, the partnership is now extending into the Canadian market which is poised to see more than 90 percent of Canadians becoming digital natives by 2023.*
As remote work went from “new normal” to “status quo” over the last two years, enterprises have witnessed an increased dependency on mobile devices for work and are concerned about business continuity challenges. To solve this, Samsung Care+ for Business is set to deliver a complete solution for device protection, thereby maximizing business productivity.
Servify will be responsible for overall management and administration of the program, together with system integration with Samsung’s authorized repair partners. Leveraging Servify’s post-sales product ownership experience platform, Samsung is poised to deliver protection with a combined coverage term of up to 3 years.**
|
Benefits for Enterprises |
|
|
|
“We are thrilled to have partnered with Samsung for their B2B program in Canada. Our ongoing alliance with Samsung covers several regions including US, Eastern Europe, KSA, UAE and India which reiterates the trust Samsung has in our capabilities,” said Sreevathsa Prabhakar, Founder of Servify.
“Today’s businesses are making significant investments in devices, and we believe it is our job to help them be prepared for any issues with seamless, automated device management tools. Samsung Care+ for Business, enabled by Servify’s platform and underpinned by Samsung’s authorized repair services for physical damage and liquid intrusion protection, will prove beneficial for businesses as they need to anticipate when devices are reaching end-of-life, determine if they are vulnerable to security breaches, and resolve a host of other issues before such issues create operational delays,” said Steven Cull , Head of Mobile Product Management, Services and Strategy, at Samsung Canada.
Samsung Care+ for Business provides its customers a worry-free protection plan, guaranteed Samsung certified service and hassle-free process for claims and tech support.
* https://www.statista.com/topics/4865/internet-usage-in-canada/#dossierKeyfigures
** Manufacturer's limited warranty is 1 year, plus up to 2 years of extended warranty - for a total of up to 3 years warranty. Available on certain Samsung devices, including Galaxy XCover and Tab Active Series devices. For physical damage and liquid intrusion service requests, two (2) covered claims are allowed per each 12-month period during the duration of the Samsung Care+ for Business.
About Samsung
Samsung Electronics Canada inspires Canadians to reach their full potential through a transformative ecosystem of products and services that deliver innovation and distinct design to every aspect of their connected lives. The company is redefining the worlds of TVs, smartphones and wearable devices, tablets and digital appliances. In 2022, Samsung was ranked as one of Canada's "Most Reputable Companies" in Léger's Corporate Reputation Study. Dedicated to helping make a difference in the lives of Canadians, Samsung's award-winning corporate giving initiatives support public education and health-related issues in communities across the country. To discover more, please visit www.Samsung.ca.
About Servify
Servify integrates multiple OEM Brands and their sales and service ecosystem through its product lifecycle management platform, to deliver great after-sales service experience. Started in 2015, India Headquartered Servify has spread its reach in multiple countries across the globe, partnering with over 75 OEM brands including top mobile device brands, retailers, distributors, insurers, service providers and carriers. The Servify platform processes more than 3 million transactions monthly, with 250k+ Platform users spread across retailers, service centres, contact centres and administration teams worldwide serving millions of consumers.
Additional information on Servify is available at www.servify.tech.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220609005582/en/
Contact information
Debapriya Ghosh Biswas
Director - Marketing
+91-9833086156; debapriya.g@servify.tech
Rethu Panicker
Senior Manager - Corporate Communications
+91-9867181043; rethu.p@servify.tech
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA and chemotherapy regimen, demonstrating an improved OS hazard ratio, continued durable outcomes, and a generally manageable safety profile. These results reinforce findings from IA1, in which the regimen met the progression-free survival (PFS) and OS endpoints, wi
GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 10:00:00 EEST | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
